EMA Authorised: Toujeo (previously Optisulin) (insulin glargine) — Sanofi-aventis Deutschland GmbH

View source ↗

Summary

The European Medicines Agency authorised Toujeo, a long-acting insulin glargine product, for diabetes mellitus with Sanofi-aventis Deutschland GmbH as the marke…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• TOUJEO (insulin glargine)

Snippet

Status: Authorised. Therapeutic area: Diabetes Mellitus. MAH: Sanofi-aventis Deutschland GmbH. Decision date: 05/03/2026